Resultados de búsqueda - David R. Fogelman

Limitar resultados
  1. 1
    Perfusion Computed Tomography as Functional Biomarker in Randomized Run-In Study of Bevacizumab and Everolimus in Well-Differentiated Neuroendocrine Tumors

    Perfusion Computed Tomography as Functional Biomarker in Randomized Run-In Study of Bevacizumab and Everolimus in Well-Differentiated Neuroendocrine Tumors por James C. Yao, Alexandria T. Phan, Kenneth R. Hess, David R. Fogelman, Carmen Jacob, Cecile G. Dagohoy, Colleen Leary, Keping Xie, Chaan S. Ng

    Publicado 2014
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  2. 2
    Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

    Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma por Reham Abdel‐Wahab, Gauri R. Varadhachary, Priya Bhosale, Xuemei Wang, David R. Fogelman, Rachna T. Shroff, Michael J. Overman, Robert A. Wolff, Milind Javle

    Publicado 2018
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    Chemotherapy with 5‐fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma

    Chemotherapy with 5‐fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma por Michael J. Overman, Scott Kopetz, Sijin Wen, Paulo M. Hoff, David R. Fogelman, Jeffrey S. Morris, James L. Abbruzzese, Jaffer A. Ajani, Robert A. Wolff

    Publicado 2008
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  4. 4
    Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline <i>BRCA</i> Variants

    Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline <i>BRCA</i> Variants por Milind Javle, Einat Shacham‐Shmueli, Lianchun Xiao, Gauri Varadhachary, Naama Halpern, David R. Fogelman, Ben Boursi, Syeda Uruba, Ofer Margalit, Robert A. Wolff, Talia Golan

    Publicado 2021
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

    Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies por Milind Javle, Rachna T. Shroff, Henry Xiong, Gauri Varadhachary, David R. Fogelman, Shrikanth A.G. Reddy, Darren W. Davis, Yujian Zhang, Robert A. Wolff, James L. Abbruzzese

    Publicado 2010
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study

    Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study por Alexandria T. Phan, Daniel M. Halperin, Jennifer A. Chan, David R. Fogelman, Kenneth R. Hess, Paige Malinowski, Eileen Regan, Chaan S. Ng, James C. Yao, Matthew H. Kulke

    Publicado 2015
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    Home-based exercise during preoperative therapy for pancreatic cancer

    Home-based exercise during preoperative therapy for pancreatic cancer por An Ngo‐Huang, Nathan Parker, Xuemei Wang, Maria Q. B. Petzel, David R. Fogelman, Keri Schadler, Éduardo Bruera, Jason B. Fleming, Jeffrey E. Lee, Matthew H. G. Katz

    Publicado 2017
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    Association between frailty syndrome and survival in patients with pancreatic adenocarcinoma

    Association between frailty syndrome and survival in patients with pancreatic adenocarcinoma por An Ngo‐Huang, Holly M. Holmes, Jude K. A. des Bordes, Nathan Parker, David R. Fogelman, Maria Q. B. Petzel, Juhee Song, Éduardo Bruera, Matthew H. G. Katz

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer

    Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer por Jennifer B. Goldstein, Li Zhao, Xuemei Wang, Yael Ghelman, Michael J. Overman, Milind Javle, Rachna T. Shroff, Gauri R. Varadhachary, Robert A. Wolff, Florencia McAllister, P. Andrew Futreal, David R. Fogelman

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer

    Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer por Van K. Morris, Michael J. Overman, Zhi-Qin Jiang, Christopher R. Garrett, Shweta Agarwal, Cathy Eng, Bryan K. Kee, David R. Fogelman, Arvind Dasari, Robert A. Wolff, Dipen M. Maru, Scott Kopetz

    Publicado 2014
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma

    Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma por David R. Fogelman, Elizabeth A. Sugar, George R. Oliver, Neeraj Shah, Alison P. Klein, Christine Alewine, Huamin Wang, Milind Javle, Rachna T. Shroff, Robert A. Wolff, James L. Abbruzzese, Daniel A. Laheru, Luis A. Díaz

    Publicado 2015
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    <i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma

    <i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma por Krittiya Korphaisarn, Van K. Morris, Michael J. Overman, David R. Fogelman, Bryan K. Kee, Kanwal Raghav, Shanequa Manuel, Imad Shureiqi, Robert A. Wolff, Cathy Eng, David G. Menter, Stanley R. Hamilton, Scott Kopetz, Arvind Dasari

    Publicado 2017
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  13. 13
    Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients

    Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients por Claudia Alvarez Florez Bedoya, Ana Carolina Ferreira Cardoso, Nathan Parker, An Ngo‐Huang, Maria Q. B. Petzel, Michael P. Kim, David R. Fogelman, Salvador Gabriel Romero, Huamin Wang, Minjeong Park, Matthew H. G. Katz, Keri Schadler

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  14. 14
    Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer

    Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer por Michael J. Overman, L. Adam, Kanwal Raghav, J. Wang, Bryan K. Kee, David R. Fogelman, Cathy Eng, Eduardo Vilar, Rachna T. Shroff, Arvind Dasari, Robert A. Wolff, Jeffrey S. Morris, Enusha Karunasena, Thomas R. Pisanic, Nilofer S. Azad, Scott Kopetz

    Publicado 2017
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  15. 15
    Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

    Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer por David R. Fogelman, Antonio Cubillo, Pilar García‐Alfonso, María Luisa Limón Mirón, John Nemunaitis, Daniel Flora, Christophe Borg, Laurent Mineur, J.M. Viéitez, Allen Lee Cohn, Gene Saylors, Albert Assad, Julie Switzky, Li Zhou, Johanna C. Bendell

    Publicado 2018
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  16. 16
    Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma

    Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma por Krittiya Korphaisarn, Van K. Morris, Jennifer S. Davis, Michael J. Overman, David R. Fogelman, Bryan K. Kee, Arvind Dasari, Kanwal Raghav, Imad Shureiqi, Metha Trupti, Robert A. Wolff, Cathy Eng, David G. Menter, Stanley R. Hamilton, Scott Kopetz

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  17. 17
    The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy

    The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy por Christina L. Roland, Matthew H. G. Katz, Ching‐Wei D. Tzeng, Heather Lin, Gauri R. Varadhachary, Rachna T. Shroff, Milind Javle, David R. Fogelman, Robert A. Wolff, Jean N. Vauthey, Christopher H. Crane, Jeffrey E. Lee, Jason B. Fleming

    Publicado 2015
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  18. 18
    Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer

    Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer por Seyed Pairawan, Kenneth R. Hess, Filip Janků, Nora Sánchez, Kenna Shaw, Cathy Eng, Senthilkumar Damodaran, Milind Javle, Ahmed O. Kaseb, David S. Hong, Vivek Subbiah, Siqing Fu, David R. Fogelman, Victoria M. Raymond, Richard B. Lanman, Funda Meric‐Bernstam

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  19. 19
    High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer

    High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer por Sarah A. Bannon, Maria F. Montiel, Jennifer B. Goldstein, Wenli Dong, Maureen E. Mork, Ester Borràs, Merve Hasanov, Gauri R. Varadhachary, Anirban Maitra, Matthew H. G. Katz, Lei Feng, P. Andrew Futreal, David R. Fogelman, Eduardo Vilar, Florencia McAllister

    Publicado 2018
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  20. 20
    Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy

    Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy por Jordan M. Cloyd, Graciela M. Nogueras‐González, Laura R. Prakash, Maria Q. B. Petzel, Nathan Parker, An Ngo‐Huang, David R. Fogelman, Jason W. Denbo, Naveen Garg, Michael P. Kim, Jeffrey E. Lee, Ching‐Wei D. Tzeng, Jason B. Fleming, Matthew H. G. Katz

    Publicado 2017
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: